[Use of a mini-sequencing test, followed by the MALDI-TOF mass-spectrometric analysis to evaluate rifampicin and izoniazid resistance in Mycobacterium tuberculosis circulating in the Russian Federation].
Afanas'ev
M V
MV
Ikriannikova
L N
LN
Il'ina
E N
EN
Smirnova
T G
TG
Larionova
E E
EE
Kuz'min
A V
AV
Chernousova
L N
LN
Kamaev
E Iu
EIu
Skorniakov
S N
SN
Kinsht
V N
VN
Cherednichenko
A G
AG
Govorun
V M
VM
D000995:Antitubercular Agents / Q000494:pharmacology; D004269:DNA, Bacterial / Q000032:analysis*; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D010641:Phenotype; D015203:Reproducibility of Results; D012293:Rifampin / Q000494:pharmacology*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology
D000995:Antitubercular Agents; D004269:DNA, Bacterial; D007538:Isoniazid; D012293:Rifampin